股市必读：舒泰神（300204）10月24日董秘有最新回复

Core Viewpoint - The company Shuyou Shen (300204) is undergoing a stock issuance process to raise funds for innovative drug research and to supplement working capital, amidst ongoing financial challenges and regulatory scrutiny [4][6][7]. Group 1: Stock Performance and Trading Information - As of October 24, 2025, Shuyou Shen's stock closed at 33.97 yuan, down 4.39%, with a turnover rate of 8.43% and a trading volume of 382,200 shares, amounting to a transaction value of 1.309 billion yuan [1]. - On the same day, the net outflow of main funds was 241 million yuan, while retail investors saw a net inflow of 250 million yuan [2]. Group 2: Financial Performance - For the fiscal year 2024, the company reported total assets of 1,149,607,757.17 yuan and total liabilities of 232,846,415.32 yuan, with a net profit of -147,731,291.05 yuan and a negative cash flow from operating activities of -63,682,894.36 yuan [3]. Group 3: Stock Issuance Details - The company plans to issue A-shares to specific investors, aiming to raise up to 1.253 billion yuan, with 883 million yuan allocated for innovative drug research and 370 million yuan for working capital [4][6]. - The issuance has been approved by the board and shareholders, but is pending review by the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission [5][7]. Group 4: Research and Development Focus - The company focuses on the development of innovative biopharmaceuticals targeting infectious diseases, respiratory and critical illnesses, autoimmune diseases, and neurological disorders, with several projects in advanced clinical trial stages [5][6].